Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease.

ABSTRACT:

Introduction

Sickle cell disease (SCD) is a common hemoglobinopathy worldwide that causes painful crises and hospitalization of patients. These attacks decrease survival and cause chronic end-organ damage in these patients.

Hypothesis

For this reason, finding new treatment approaches could be helpful.

Method

In this study, Imatinib was applied as a mast cell inhibitor to reduce pain crises in these patients. Seven patients resistant to hydroxyurea and folic acid treatment and who had at least four painful crises per year with hospitalization were enrolled in this study with treatment with Imatinib (100 mg, twice daily). Subsequently, the number and duration of hospitalizations, analgesic requirement, the severity of chronic pain, and changes in the hematological param

SUBMITTER: Karimi M 

PROVIDER: S-EPMC11451392 | biostudies-literature | 2024 Oct-Dec

REPOSITORIES: biostudies-literature